Lucid Diagnostics Inc. · NASDAQ:LUCD

Lucid Diagnostics — Q4 2025 Earnings Presentation

13 slides from Lucid Diagnostics's earnings presentation, Mar 26, 2026

  1. Slide 1: Q4 2025 Business Update

    Nasdaq: LUCD Q4 2025 Business Update March 26, 2026 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO

  2. Slide 2: Disclaimer

    Disclaimer ▪ This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the “Company”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors th

  3. Slide 3: Lishan Aklog, M.D. Chairman & CEO

    Lishan Aklog, M.D. Chairman & CEO

  4. Slide 4: Highlights

    Highlights ▪ Key Highlights – 4Q25 EsoGuard test volume: 3,664 – 4Q25 Revenue: $1.5M – Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard, expanding access across the nation’s largest integrated healthcare system – Announced positive data from the largest reported real-world expe

  5. Slide 5: Business Update

    ms (b) Lucid diagnostics Business Update

  6. Slide 6: Reimbursement Update

    Reimbursement Update Multi-Payor Medical Policy (LBM) (Utilization Coverage Pathway Management) 6

  7. Slide 7: VA Healthcare System Implementation

    VA Healthcare System Implementation 7

  8. Slide 8: Q4 2025 Financial Update

    Q4 2025 Financial Update Dennis McGrath, CFO

  9. Slide 9: Balance Sheet

    Balance Sheet ($ in thousands) 4Q25 4Q24 Change Assets Cash $34,705 $22,358 $12,347 Fixed Assets $809 $1,062 $(253) All other Assets $4,931 $7,295 $(2,364) Liabilities Accounts Payable $970 $1,241 $(271) Senior Secured Convertible Notes $24,000 $18,600 $5,400 Other Current Liabilities $3,612 $3,683

  10. Slide 10: P&L

    P&L ($ in thousands) 4Q25 4Q24 Change 2025 2024 Change Revenue $1,504 $1,197 $307 $4,706 $4,346 $360 Operating Expenses $15,514 $13,571 $1,943 $54,346 $50,398 $3,948 Net Loss $(16,266) $(11,541) $(4,725) $(70,569) $(53,025) $(17,544) 1 EBITDA $(16,160) $(11,377) $(4,783) $(57,502) $(44,658) 3 $(12,8

  11. Slide 11: Non-GAAP Operating Expense

    Non-GAAP Operating Expense 8,000 16,000 7,000 14,139 14,000 12,079 11,990 6,000 11,109 12,000 11,511 5,000 10,000 4,000 8,000 3,000 6,000 2,000 4,000 1,000 2,000 0 0 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Cost of Revenue Sales and Marketing General & Admin R&D Total To supplement our audited financ

  12. Slide 12: Q&A

    Q&A

  13. Slide 13: Closing Remarks

    ms (b) Lucid diagnostics Closing Remarks

Lucid Diagnostics — Q4 2025 Earnings Presentation on 6ix